DANBURY, Conn., June 11, 2013 (GLOBE NEWSWIRE) -- ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in single-use bioprocess solutions, announced today the opening of a United States-based laboratory for applications development and testing. Located inside its Bloomington, MN manufacturing facility, the lab has been opened to support process operations using the full ATMI LifeSciences portfolio of single-use bioprocess solutions, including bioprocess vessels, bioreactors, mixers and its fill/finish platform. The site is a duplicate of ATMI's original laboratory located in Brussels, Belgium, and is part of the company's strategy of implementing interactive, long-term customer support along with their innovative single-use disposable technologies.
The Belgium lab was introduced in Brussels in 2008 to develop and validate the Integrity® iCELLis® and Xpansion™ bioreactors. However, the scope of the lab quickly grew to include full support services for all ATMI LifeSciences technologies. With the addition of the new 100 square meter, fully equipped Bloomington laboratory, ATMI has extended this depth of support to U.S.-based customers. Together, the labs offer direct access to the expertise of 15 global application specialists and scientists that are dedicated to working on customer bioprocess development efforts.
"The new location is a clear reflection of ATMI's strategy to provide comprehensive bioprocess solutions and invest in customer support," noted Senior Vice President and General Manager of ATMI LifeSciences, Mario Phillips. "The laboratory is fully equipped with ATMI technologies and equipment to perform cell culture, and it is staffed by experts in the field. The team at this site has extensive experience in cell culture bioprocesses development and scale-up, as well as more than 20 protein, virus and cell production processes that have been developed in ATMI's proprietary bioreactors. The team will be fully focused on understanding the challenges that customers are faced with and applying their technical knowledge to offer guidance."
The new Bloomington lab features development and operations support in a round-the-clock format. Customers taking advantage of the lab can benefit from the ability to align directly with application staff to develop and optimize processes, test bioprocess applications, scale-up individual cell culture processes for technical transfer, learn through demonstrations how ATMI technologies work, and receive any further training that may be needed.
"ATMI's single-use technologies can often be considered disruptive because they are bringing innovative new concepts to life," said Director of Applications for ATMI LifeSciences, Richard Bhella. "Customers often tell us they want to integrate our technologies, but don't know how. These laboratories are important because they provide full customer support from our application and scientific staff and act as a cornerstone of innovation for ATMI. They provide direct access to our newest technologies."
The Bloomington laboratory went live in April 2013. For more information, or to schedule a visit to the site, please contact site manager Stéphanie Dubois by email at email@example.com. Stéphanie will also be available to take inquiries and schedule site visits at the upcoming 23rd ESACT meeting from June 23rd to 26th at the Grand Palais in Lille, France.
ATMI, Inc. provides specialty semiconductor materials, and safe, high-purity materials handling and delivery solutions designed to increase process efficiencies for the global semiconductor, flat panel, and life sciences industries. For more information, please visit http://www.atmi.com.
About ATMI LifeSciences
ATMI LifeSciences is an acknowledged technology leader in the field of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries. Its innovative, market-leading portfolio of custom-engineered, flexible packaging solutions, single-use storage systems, mixers and bioreactors is driving bioprocess efficiency and delivering value for biopharmaceutical companies around the world. For more information, please visit www.atmi-lifesciences.com.
ATMI, the ATMI logo, Integrity, iCELLis and Xpansion are trademarks, or registered trademarks, of Advanced Technology Materials, Inc., in the United States, other countries or both.
Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI's anticipated results of operations or level of business for 2013 or any other future period, are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations only and are subject to certain risks, uncertainties, and assumptions, including, but not limited to, changes in semiconductor and life sciences industry growth (including, without limitation, wafer starts) or ATMI's markets; competition, problems, or delays developing, commercializing, and delivering new products; customer-driven pricing pressure; potential loss of key customers; problems or delays in integrating acquired operations and businesses; uncertainty in the credit and financial markets; ability to protect ATMI's proprietary technology; and other factors described in ATMI's Form 10-K for the year ended December 31, 2012 and other subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties may cause actual results to differ materially from those expressed in our forward-looking statements. ATMI undertakes no obligation to update any forward-looking statements.